Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.